Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma
Completed · Phase 3
Conditions studied: Multiple Myeloma and Plasma Cell Neoplasm
In brief
RATIONALE: Zoledronate may prevent bone loss and stop the growth of cancer cells in bone. Thalidomide may stop the growth of cancer cells by blocking blood flow to the cancer. It is not yet know whether giving zoledronate together with thalidomide is more effective than zoledronate alone in treating multiple myeloma. PURPOSE: This randomized phase III trial is studying zoledronate and thalidomide see how well they work compared with zoledronate alone in treating patients with early stage multiple myeloma.
Key facts
- Study ID
- NCT00432458
- Run by
- Mayo Clinic
- People needed
- 68
- Starts
- 2003-07-01
- Expected to finish
- 2012-04-01
- Last updated by the study team
- 2012-07-04
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mayo Clinic Scottsdale — Scottsdale, Arizona, United States
- Mayo Clinic - Jacksonville — Jacksonville, Florida, United States
- Mayo Clinic Cancer Center — Rochester, Minnesota, United States
- Memorial Sloan-Kettering Cancer Center — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.